BAYN:XETR

Bayer AG is trading at €37.59, well below its DCF‑derived fair value of €89.81, implying roughly a 20% upside according to the model. Technical indicators show a bullish trend with the 20‑day SMA (€42.70) above the 50‑day SMA (€42.32) and price comfortably above the identified support at €35.20, while the RSI of 34 suggests the stock is nearing oversold conditions. The MACD line remains negative and below its signal, signaling short‑term bearish momentum, yet the overall trend direction is flagged as bullish. Recent market sentiment is extremely positive – the Fear & Greed Index reads 75.9 (“Extreme Greed”) and news reports note a 2.5% share surge on recovery signs. Fundamentally, revenue has slipped 2.5% year‑over‑year and profit margins are negative, with a -7.9% net margin and a ROE of -12.4%, reflecting ongoing earnings pressure. The balance sheet is heavily leveraged (debt‑to‑equity ≈ 144), and the dividend payout ratio exceeds 160%, raising sustainability concerns. However, forward EPS of €4.80 and a forward P/E of 7.84 contrast sharply with the industry average P/E of 25.4, indicating a potential value play. The stock’s beta is low (≈ 0.30), suggesting limited market‑wide volatility, but 30‑day price volatility is high at 44%, and the historical max drawdown sits at –26%. With a market cap of €36.9 bn and stable trading volumes, liquidity is adequate. In sum, Bayer appears undervalued on a price‑to‑value basis, but earnings weakness, debt load, and dividend sustainability temper optimism.